As part of its defense, Novo Nordisk points to its compliance with regulatory agencies, including the FDA
Topics include structural and functional equivalence demonstration, comprehensive analytical characterization strategies (including higher-order structure analysis and mass spectrometry), peptide-specific stability challenges and shelf-life determinations, impurity profiling and characterization, and an update on peptide impurity qualification
The Roles of Autoimmunity and Biotoxicosis in Sick Building Syndrome as a Starting Point for Irreversible Dampness and Mold Hypersensitivity Syndrome
GLP-1 receptor agonists, liraglutide and lixisenatide, also display neuroprotective properties in MPTP mouse models
It was discontinued in 2008 for manufacturing reasons, not safety concerns
Wang S, He G, Chen M, Zuo T, Xu W, Liu X